There is more to this news than meets the eye.

In this week’s edition of InnovationRx, we look at the Forbes 30 Under 30 Healthcare list, the coming barriers to getting ...

By Rishika Sadam HYDERABAD, India, Dec 3 (Reuters) - Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar with the matter said, ...

Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two disappointing ...

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...

India has the second-highest number of people with type 2 diabetes after China and rising obesity rates, making it a critical battleground for drugmakers ...

A key catalyst may be right around the corner.

Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

The order follows the court’s view that Novo Nordisk’s patent appears prima facie invalid -- a finding that could reshape ...

he Danish pharmaceutical giant has been steadily expanding its presence in India, and the arrival of Ozempic marks a significant move in a country grappling with fast-rising rates of type 2 diabetes ...

According to JM Financial, the decision is a positive development for both Dr Reddy's and OneSource as it allows continuous manufacturing and the accumulation of inventory. This stock can later be dep ...

Experts unpack the implications of CBER Director Vinay Prasad’s claim that COVID vaccines have caused 10+ child deaths; the ...